-+ 0.00%
-+ 0.00%
-+ 0.00%

Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy

PUBT·06/05/2026 13:21:03
Listen to the news
Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy
  • Bellevue Group highlighted Roche’s push into AI-driven R&D; giredestrant flagged as a potential multi-billion-dollar breast cancer drug.
  • BridgeBio’s Attruby described as tracking toward multi-billion-dollar potential; management targets profitability by 2027, cites USD 8 billion combined peak sales.
  • Cogent Biosciences faces two late-2026 FDA decisions for bezuclastinib; approval could shift it from development-stage to commercial operations.
  • Compass Pathways expects to file in Q4 for treatment-resistant depression; potential approval late 2027, DEA scheduling expected 2-4 months later.
  • Inventiva expects Phase III lanifibranor readout in Q4; management focuses on fibrosis reversal, with upside tied to clinical data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bellevue Group AG published the original content used to generate this news brief on June 05, 2026, and is solely responsible for the information contained therein.